CROSSLINKING OLIGONUCLEOTIDES FOR THERAPY AND DIAGNOSIS

Information

  • Research Project
  • 3506655
  • ApplicationId
    3506655
  • Core Project Number
    R44CA045905
  • Full Project Number
    5R44CA045905-03
  • Serial Number
    45905
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/30/1987 - 36 years ago
  • Project End Date
    8/31/1992 - 31 years ago
  • Program Officer Name
  • Budget Start Date
    9/1/1990 - 33 years ago
  • Budget End Date
    8/31/1992 - 31 years ago
  • Fiscal Year
    1990
  • Support Year
    3
  • Suffix
  • Award Notice Date
    8/20/1990 - 33 years ago
Organizations

CROSSLINKING OLIGONUCLEOTIDES FOR THERAPY AND DIAGNOSIS

We will attach substituents terminating in an electrophilic alkylating moiety to certain of the heterocyclic bases in synthetic oligonucleotides for the purpose of covalent alkylation of nucleophilic sites on the complementary target strand after the initial hybrid has been formed between oligomer and target. Our criteria for a successful crosslinking oligonucleotide will be adequate speed of crosslinking, specificity of attack, stability in relevant biological conditions, and relative ease of synthesis. If these criteria can be met, oligonucleotides with these crosslinking modifications will have great potential in both the antisense oligonucleotide field of chemotherapeutic drug discovery, especially in the area of antiviral drugs, and in the DNA probe-based diagnostics filed. In the former area, the modification will give a substantial increase in potency in the inhibition of mRNA translation, and should be able to inactivate transcription and replication of specifically targeted genes. In the latter case, a dramatic increase in signal-to-noise of the assay should result since much more stringent washes may be employed.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R44
  • Administering IC
    CA
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    395
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    ET
  • Study Section Name
    Experimental Therapeutics Subcommittee 2
  • Organization Name
    EPOCH BIOSCIENCES, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    BOTHELL
  • Organization State
    WA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    980213906
  • Organization District
    UNITED STATES